Guardian Pharmacy Services (NYSE:GRDN) Shares Up 5.4% – Time to Buy?

Guardian Pharmacy Services, Inc. (NYSE:GRDN) rose 5.4% on Tuesday . The company traded as high as $39.34 and last traded at $39.11. 328,979 shares changed hands during trading, a decline of 15% from the average session volume of 386,244 shares. The stock had previously closed at $37.09.

Analyst Ratings Changes

Several brokerages have recently issued reports on GRDN. Bank of America boosted their price target on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Zacks Research lowered Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Oppenheimer lifted their target price on Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a report on Friday, August 7th. Truist Financial boosted their target price on Guardian Pharmacy Services from $43.00 to $47.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. Finally, Weiss Ratings upgraded Guardian Pharmacy Services from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, August 20th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Guardian Pharmacy Services presently has an average rating of “Moderate Buy” and a consensus price target of $43.83.

Guardian Pharmacy Services Price Performance

The stock’s 50 day simple moving average is $39.79 and its two-hundred day simple moving average is $37.93. The stock has a market cap of $1.94 billion, a P/E ratio of 37.83, a price-to-earnings-growth ratio of 1.92 and a beta of 0.11.

Guardian Pharmacy Services (NYSE:GRDN) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.03. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. The company had revenue of $351.77 million during the quarter, compared to analysts’ expectations of $340.45 million. As a group, analysts forecast that Guardian Pharmacy Services, Inc. will post 1.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Guardian Pharmacy Services

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GRDN. Ameritas Investment Partners Inc. increased its holdings in Guardian Pharmacy Services by 26.5% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after purchasing an additional 345 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Guardian Pharmacy Services in the second quarter valued at about $43,000. State of Wyoming bought a new stake in shares of Guardian Pharmacy Services in the second quarter valued at about $58,000. Strs Ohio acquired a new position in shares of Guardian Pharmacy Services during the fourth quarter worth about $75,000. Finally, Clearstead Advisors LLC boosted its position in shares of Guardian Pharmacy Services by 196.3% during the fourth quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock worth $79,000 after buying an additional 1,741 shares during the period.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.